Compare Terminalcare Support Institute, Inc. with Similar Stocks
Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- High Debt Company with a Debt to Equity ratio (avg) at times
2
High Debt company with Weak Long Term Fundamental Strength
3
Flat results in Dec 25
4
With ROCE of 3.66%, it has a expensive valuation with a 0.97 Enterprise value to Capital Employed
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 1,234 Million (Micro Cap)
11.00
NA
0.00%
1.91
5.07%
0.91
Revenue and Profits:
Net Sales:
1,376 Million
(Quarterly Results - Dec 2025)
Net Profit:
58 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.15%
0%
-3.15%
6 Months
-4.49%
0%
-4.49%
1 Year
-18.24%
0%
-18.24%
2 Years
-38.09%
0%
-38.09%
3 Years
-58.4%
0%
-58.4%
4 Years
-61.71%
0%
-61.71%
5 Years
0%
0%
0.0%
Terminalcare Support Institute, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.15%
EBIT Growth (5y)
-6.70%
EBIT to Interest (avg)
5.55
Debt to EBITDA (avg)
4.63
Net Debt to Equity (avg)
1.57
Sales to Capital Employed (avg)
1.17
Tax Ratio
35.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.88%
ROE (avg)
10.08%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
0.92
EV to EBIT
26.47
EV to EBITDA
13.27
EV to Capital Employed
0.97
EV to Sales
0.68
PEG Ratio
0.11
Dividend Yield
NA
ROCE (Latest)
3.66%
ROE (Latest)
8.18%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
1,376.40
1,247.40
10.34%
Operating Profit (PBDIT) excl Other Income
120.80
57.70
109.36%
Interest
13.20
12.40
6.45%
Exceptional Items
0.00
0.00
Consolidate Net Profit
57.70
35.80
61.17%
Operating Profit Margin (Excl OI)
48.50%
6.60%
4.19%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 10.34% vs 6.52% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 61.17% vs 105.75% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
4,886.20
4,707.90
3.79%
Operating Profit (PBDIT) excl Other Income
205.10
250.60
-18.16%
Interest
47.70
29.90
59.53%
Exceptional Items
0.00
45.00
-100.00%
Consolidate Net Profit
82.00
113.80
-27.94%
Operating Profit Margin (Excl OI)
6.60%
28.20%
-2.16%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.79% vs 10.69% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -27.94% vs -10.18% in Dec 2024
About Terminalcare Support Institute, Inc. 
Terminalcare Support Institute, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






